Holen Sie sich die Stockscreener-App
228.87
0.53%
1.20
Handel nachbörslich:
228.87
Schlusskurs vom Vortag:
$227.67
Offen:
$230
24-Stunden-Volumen:
492.87K
Relative Volume:
4.48
Marktkapitalisierung:
$24.42B
Einnahmen:
$3.32B
Nettoeinkommen (Verlust:
$-860.46M
KGV:
-27.51
EPS:
-8.32
Netto-Cashflow:
$-1.04B
1W Leistung:
+0.87%
1M Leistung:
+26.70%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$227.25
$233.50
1-Wochen-Bereich:
$216.88
$233.50
52-Wochen-Spanne:
$172.67
$233.50
Beigene Ltd Adr Stock (ONC) Company Profile
Firmenname
Beigene Ltd Adr
Sektor
Branche
Telefon
13459494123
Adresse
C/O MOURANT GOVERNANCE SERVICES (CAYMAN), GRAND CAYMAN
Vergleichen Sie ONC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ONC
Beigene Ltd Adr
|
228.87 | 24.42B | 3.32B | -860.46M | -1.04B | -8.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Beigene Ltd Adr Stock (ONC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2024-09-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-02-06 | Fortgesetzt | JP Morgan | Overweight |
| 2023-09-12 | Eingeleitet | Macquarie | Outperform |
| 2023-08-17 | Eingeleitet | Jefferies | Buy |
| 2023-07-17 | Eingeleitet | Citigroup | Buy |
| 2023-06-30 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2023-01-12 | Eingeleitet | Daiwa Securities | Buy |
| 2022-10-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-10-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-08-09 | Fortgesetzt | JP Morgan | Overweight |
| 2022-03-17 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-02-07 | Eingeleitet | Deutsche Bank | Buy |
| 2021-10-12 | Eingeleitet | Bernstein | Outperform |
| 2021-10-06 | Hochstufung | CLSA | Underperform → Buy |
| 2021-03-08 | Eingeleitet | China Renaissance | Buy |
| 2021-03-01 | Herabstufung | CLSA | Outperform → Underperform |
| 2020-11-09 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-06 | Herabstufung | Maxim Group | Buy → Hold |
| 2020-11-06 | Herabstufung | Piper Sandler | Neutral → Underweight |
Alle ansehen
Beigene Ltd Adr Aktie (ONC) Neueste Nachrichten
Beigene's Wang Xiaodong sells $9.4 million in shares - Investing.com
Orphan Designated Drugs Market Analysis: Key Trends, Players and Forecasts for Future Growth - GlobeNewswire Inc.
CCBI Adds BEIGENE's TP to $179 for Better Fundamentals This Yr - AASTOCKS.com
BEIGENE (06160.HK) Climbs 6% in Early Session, Expects to Achieve Positive Operating Income This Yr - AASTOCKS.com
Beigene director Wang Xiaodong sells $7.37 million in shares - Investing.com
HSBC Global Research Prefers BeiGene/ SINO BIOPHARM/ HYGEIA HEALTH Given Higher Visibility in CN Pharma & Medical Device Subsectors - AASTOCKS.com
(NASDAQ:BGNE) Stock Quotes, Forecast and News Summary - Benzinga
FDA approves BeiGene's TEVIMBRA for advanced gastric cancer treatment - Investing.com
With 45% institutional ownership, BeiGene, Ltd. (NASDAQ:BGNE) is a favorite amongst the big guns - Yahoo Finance
Weekly Upgrades and Downgrades - InvestorPlace
BeiGene shares reiterate Buy rating on robust oncology pipeline - Investing.com
Beigene directors sell shares worth $194.2 million - Investing.com
Beigene sees $274 million stock sale by Hillhouse Investment By Investing.com - Investing.com
10 High Growth Healthcare Stocks to Invest in Now - Insider Monkey
10 Biggest Biotechnology Companies - Investopedia
BeiGene announces name change to BeOne Medicines Ltd. - Investing.com
BeiGene announces passing of board member Donald Glazer - Investing.com
BeiGene stock momentum builds on Brukinsa success, says JPMorgan's Fye - Investing.com
BeiGene CEO John Oyler sells shares worth over $3.75 million - Investing.com
BeiGene's SVP sells shares worth nearly $285k - Investing.com
BeiGene executive sells over $1.1m in company shares - Investing.com
JMP calls BeiGene a 'unique investment opportunity', sets $288 shares target By Investing.com - Investing.com
CCBI Lowers BEIGENE (06160.HK) TP to $140, Solid 2Q Results Expected - AASTOCKS.com
Nomura Raises BEIGENE (06160.HK)'s TP to $158.37 and Rev. Forecast for FY24/FY25 - AASTOCKS.com
BeiGene CFO sells over $145,000 in company stock - Investing.com
BeiGene's (BGNE) Shares Surge 32% in a Month: Here's Why - Yahoo Finance
BofA raises BeiGene stock target to $179.30 on strong drug sales growth - Investing.com
Primecap Odyssey Funds' 2023 Semiannual Letter - GuruFocus.com
7 Best Cancer Stocks To Invest In Now - Barchart
BEIGENE On Reported 'Brukinsa' Infringement: To React when Appropriate with Vigorous Defense - AASTOCKS.com
BEIGENE Collapses 13% to Half-Yr Low With High Vol., as its Blood Cancer Drug 'Brukinsa' Get Sued for Infringement - AASTOCKS.com
HFCAA News: 128 Chinese Stocks the SEC Could Delist - InvestorPlace
Making it harder to "buy" China, Inc. - US-China Institute
What Happens to Your ETFs if Chinese ADRs Delist? - HK.Morningstar.com
Will We See a Slew of ADR Delistings? - HK.Morningstar.com
See What the Public Investment Fund Bought Recently Including Walmart and FedEx Stocks - Sovereign Wealth Fund Institute
BeiGene (BGNE) Gets FDA Nod for Brukinsa Label Expansion - Yahoo Finance
BeiGene Ltd. Sponsored ADR to Host Earnings Call - AccessWire
BeiGene: Recent Sector Weakness Offers An Attractive Entry Point (NASDAQ:ONC) - Seeking Alpha
Finanzdaten der Beigene Ltd Adr-Aktie (ONC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.99%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):